{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:29:03Z","timestamp":1769848143648,"version":"3.49.0"},"reference-count":58,"publisher":"Oncology Nursing Society (ONS)","issue":"s6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2013,12,1]]},"DOI":"10.1188\/13.cjon.s2.33-41","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T21:12:36Z","timestamp":1385500356000},"page":"33-41","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Updates in Blood and Marrow Transplantation in Multiple Myeloma"],"prefix":"10.1188","volume":"17","author":[{"given":"Beth","family":"Faiman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Lilleby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2013,11,26]]},"reference":[{"key":"1","first-page":"4059","article-title":"Cost analysis of using plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for autologous stem cell mobilization in multiple myeloma patients treated at Memorial Sloan-Kettering Cancer Center [Abstract 3537]","volume":"118","author":"N. Adel","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2","unstructured":"Amgen Inc. (2013). Neupogen<\/i>\u00ae (filgrastim)<\/i> [Package insert]. Retrieved from http:\/\/pi.amgen.com\/united_states\/neupogen\/neupogen_pi_hcp_english.pdf<\/a>"},{"key":"3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/CBO9780511575785.005","volume-title":"Manual of stem cell and bone marrow transplantation","author":"J. Antin","year":"2009"},{"key":"4","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/leu.2008.396","article-title":"Role of autologous and allogeneic stem cell transplantation in myeloma","volume":"23","author":"W. Bensinger","year":"2009","journal-title":"Leukemia"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1188\/09.ONF.E317-E325","article-title":"Hematopoietic stem cell transplantation nursing: A practice variation study [Online exclusive]","volume":"36","author":"M. Bevans","year":"2009","journal-title":"Oncology Nursing Forum"},{"key":"6","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00277-011-1275-3","article-title":"Prophylactic intravenous immunoglobulin during autologous haematopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications","volume":"90","author":"P. Blombery","year":"2011","journal-title":"Annals of Hematology"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1188\/13.CJON.E63-E67","article-title":"Evidence-based guideline recommendations: Post-hematopoietic stem cell transplantation [Online exclusive]","volume":"17","author":"M. Burkhart","year":"2013","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","article-title":"AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and\/or cytokine treatment: Compassionate use data","volume":"41","author":"G. Calandra","year":"2008","journal-title":"Bone Marrow Transplantation"},{"key":"9","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation","volume":"117","author":"M. Cavo","year":"2011","journal-title":"Blood"},{"key":"10","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4520","article-title":"Importance of achieving a complete response in multiple myeloma, and the impact of novel agents","volume":"28","author":"A. Chanan-Khan","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1188\/12.CJON.E142-E149","article-title":"Discharge needs of allogeneic transplantation recipients [Online exclusive]","volume":"16","author":"L. Cooke","year":"2012","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"12","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"J. DiPersio","year":"2009","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd2819","article-title":"Plerixafor","volume":"8","author":"J. DiPersio","year":"2009","journal-title":"Nature Reviews. Drug Discovery"},{"key":"14","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"B. Durie","year":"2006","journal-title":"Leukemia"},{"key":"15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/ajh.23412","article-title":"Long-term outcome after allogeneic stem cell transplantation with reduced-intensity conditioning in patients with multiple myeloma","volume":"88","author":"J. El-Cheikh","year":"2013","journal-title":"American Journal of Hematology"},{"key":"16","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2005-02-0468","article-title":"The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone","volume":"106","author":"N. Flomenberg","year":"2005","journal-title":"Blood"},{"key":"17","unstructured":"Genzyme Corporation. (2010). Mozobil<\/i>\u00ae (plerixafor injection)<\/i> [Package insert]. Retrieved from http:\/\/www.mozobil.com\/document\/Package_Insert.pdf<\/a>"},{"key":"18","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/bmt.2009.370","article-title":"Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma","volume":"45","author":"M. Gertz","year":"2010","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"19","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation-2011.1.191","article-title":"Stem cell transplantation for multiple myeloma: Current and future status","volume":"17","author":"S. Giralt","year":"2012","journal-title":"Hematology"},{"key":"20","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"S. Giralt","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/jca.21206","article-title":"The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells","volume":"27","author":"A. Gopal","year":"2012","journal-title":"Journal of Clinical Apheresis"},{"key":"22","unstructured":"Harvey, R. D., Lonial, S., Renfroe, H., Sinha, R., Flowers, C. R., Lechowicz, M. J., \u2026 Kaufman, J. L. (2011). Temporal changes in plerixafor administration do not impact hematopoietic stem cell mobilization efficacy: Results of a prospective clinical trial [Abstract 2988]. Retrieved from http:\/\/ash.confex.com\/ash\/2011\/webprogram\/Paper35916.html<\/a>"},{"key":"23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00520-003-0562-5","article-title":"Chemotherapy-induced alopecia: Psychosocial impact and therapeutic approaches","volume":"12","author":"P. Hesketh","year":"2004","journal-title":"Supportive Care in Cancer"},{"key":"24","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"A. Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"25","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","article-title":"Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation","volume":"30","author":"J. Koreth","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/CCO.0b013e328324bc04","article-title":"Stem cell transplantation for multiple myeloma","volume":"21","author":"S. Kumar","year":"2009","journal-title":"Current Opinion in Oncology"},{"issue":"2","key":"27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1188\/13.CJON.S2.25-32","article-title":"Caregivers of multiple myeloma survivors","volume":"17","author":"S. Kurtin","year":"2013","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"28","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1188\/06.CJON.787-794","article-title":"Immune reconstitution: The foundation for safe living after an allogeneic hematopoietic stem cell transplantation","volume":"10","author":"A. Laffan","year":"2006","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"29","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1378\/chest.08-2084","article-title":"Diffuse alveolar hemorrhage","volume":"137","author":"A. Lara","year":"2010","journal-title":"Chest"},{"key":"30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/sj.bmt.1705384","article-title":"A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation","volume":"37","author":"K. Lilleby","year":"2006","journal-title":"Bone Marrow Transplantation"},{"key":"31","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"H. Lokhorst","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/bmt.2012.5","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation","volume":"47","author":"N. Majhail","year":"2012","journal-title":"Bone Marrow Transplantation"},{"key":"33","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/bmt.2012.258","article-title":"Surviving the cure: Long term followup of hematopoietic cell transplant recipients","volume":"48","author":"N. Majhail","year":"2013","journal-title":"Bone Marrow Transplantation"},{"key":"34","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.V76.8.1464.1464","article-title":"A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment","volume":"76","author":"P. Martin","year":"1990","journal-title":"Blood"},{"key":"35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1188\/07.CJON.325-328","article-title":"Graft-versus-host disease: Review and nursing implications","volume":"11","author":"M. Mattson","year":"2007","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbmt.2012.08.010","article-title":"Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization","volume":"19","author":"I. Micallef","year":"2013","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"2","key":"37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1188\/13.CJON.S2.13-24","article-title":"Autologous hematopoietic stem cell transplantation for patients with multiple myeloma: An overview for nurses in community practice","volume":"17","author":"T. Miceli","year":"2013","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","article-title":"Comparison of 200 mg\/m2<\/sup> melphalan and 8 Gy total body irradiation plus 140 mg\/m2<\/sup> melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du My\u00e9lome 9502 randomized trial","volume":"99","author":"P. Moreau","year":"2002","journal-title":"Blood"},{"key":"39","unstructured":"National Cancer Institute. (2013). FDA approval for plerixafor. Retrieved from http:\/\/www.cancer.gov\/cancertopics\/druginfo\/fda-plerixafor<\/a>"},{"key":"40","first-page":"223","article-title":"Managing the toxicity of hematopoietic stem cell transplant","volume":"2","author":"A. Pallera","year":"2004","journal-title":"Journal of Supportive Oncology"},{"issue":"1","key":"41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","article-title":"How to manage neutropenia in multiple myeloma","volume":"12","author":"A. Palumbo","year":"2012","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"key":"42","unstructured":"Pasquini, M. C., & Wang, Z. (2011). Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2011. Retrieved from http:\/\/www.cibmtr.org\/ReferenceCenter\/SlidesReports\/SummarySlides\/Pages\/index.aspx<\/a>"},{"key":"43","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/NCC.0b013e31820641a5","article-title":"Orange interventions for symptoms associated with dimethyl sulfoxide during stem cell reinfusions: A feasibility study","volume":"34","author":"P. Potter","year":"2011","journal-title":"Cancer Nursing"},{"key":"44","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"P. Richardson","year":"2010","journal-title":"Blood"},{"key":"45","first-page":"155","volume-title":"Multiple myeloma: A textbook for nurses","author":"A. Rodriguez","year":"2010"},{"key":"46","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"L. Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"key":"47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3324\/haematol.2012.071456","article-title":"Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: Results of the prospective PREDICT trial","volume":"98","author":"N. Russell","year":"2013","journal-title":"Haematologica"},{"key":"48","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1182\/blood-2010-10-263095","article-title":"How I treat late effects in adults after allogeneic stem cell transplantation","volume":"117","author":"B. Savani","year":"2011","journal-title":"Blood"},{"key":"49","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/bmt.2009.234","article-title":"Outpatient myeloablative allo-SCT: A comprehensive approach yields decreased hospital utilization and low TRM","volume":"45","author":"S. Solomon","year":"2010","journal-title":"Bone Marrow Transplantation"},{"key":"50","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/asheducation-2010.1.237","article-title":"Comorbidities and hematopoietic cell transplantation outcomes","volume":"2010","author":"M. Sorror","year":"2010","journal-title":"Hematology"},{"key":"51","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/QCO.0b013e328348b379","article-title":"Antimicrobial prophylaxis regimens following transplantation","volume":"24","author":"A. Subramanian","year":"2011","journal-title":"Current Opinion in Infectious Diseases"},{"issue":"1","key":"52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5966\/sctm.2012-0115","article-title":"Concise review: Acute graft-versus-host disease: Immunobiology, prevention, and treatment","volume":"2","author":"A. Sung","year":"2013","journal-title":"Stem Cells Translational Medicine"},{"key":"53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1600-0609.2012.01795.x","article-title":"Effect of time to infusion of autologous stem cells (24 versus 48 hours) after high-dose melphalan in patients with multiple myeloma","volume":"89","author":"G. Talamo","year":"2012","journal-title":"European Journal of Haemoatology"},{"key":"54","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2011-12-381426","article-title":"Second malignancies after multiple myeloma: From 1960s to 2010s","volume":"119","author":"A. Thomas","year":"2012","journal-title":"Blood"},{"key":"55","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3748\/wjg.v18.i16.1851","article-title":"Gastrointestinal and hepatic complication of hematopoietic stem cell transplantation","volume":"18","author":"H. Tuncer","year":"2012","journal-title":"World Journal of Gastroenterology"},{"key":"56","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.bbmt.2009.12.534","article-title":"Strong association between respiratory viral infection early after hematopoietic stem cell transplantation and the development of life-threatening acute and chronic alloimmune lung syndromes","volume":"16","author":"A. Versluys","year":"2010","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"57","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.bbmt.2007.01.078","article-title":"Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant","volume":"13","author":"D. Weinstock","year":"2007","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"58","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/scd.1.1993.2.521","article-title":"Source of stem cell rescue: Bone marrow versus peripheral blood progenitors","volume":"2","author":"S. Williams","year":"1993","journal-title":"Journal of Hematotherapy"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/04N285273613N78J.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:54:18Z","timestamp":1763754858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/17\/6\/supplement-december-2013-multiple-myeloma\/clinical-updates-blood"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,26]]},"references-count":58,"journal-issue":{"issue":"s6","published-print":{"date-parts":[[2013,12,1]]}},"alternative-id":["04N285273613N78J"],"URL":"https:\/\/doi.org\/10.1188\/13.cjon.s2.33-41","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,26]]}}}